Anebulo Pharmaceuticals (ANEB) Non Operating Interest Expenses (2020 - 2025)

Anebulo Pharmaceuticals (ANEB) has reported Non Operating Interest Expenses for 5 consecutive years, with $17439.0 the latest figure, recorded in Q4 2025.

• On a quarterly basis, Non Operating Interest Expenses fell 82.56% year-over-year to $17439.0 in Q4 2025; TTM through Dec 2025 was $315485.0, a 14.31% decrease from a year earlier, with the FY2025 full-year figure at $400000.0, up 100.0% from the prior year.
• Non Operating Interest Expenses was $17439.0 for Q4 2025 at Anebulo Pharmaceuticals, roughly flat from $17439.0 in the prior quarter.
• Over five years, Non Operating Interest Expenses peaked at $245182.0 in Q1 2025 and troughed at $1869.0 in Q4 2021.
• A 4-year average of $65550.5 and a median of $35425.0 in 2025 frame the typical range for Non Operating Interest Expenses.
• The widest YoY moves for Non Operating Interest Expenses: up 310.72% in 2025, down 82.56% in 2025.
• Over 4 years, Non Operating Interest Expenses stood at $1869.0 in 2021, then jumped by 1603.48% to $31838.0 in 2023, then soared by 214.09% to $100000.0 in 2024, then plunged by 82.56% to $17439.0 in 2025.
• The last three Non Operating Interest Expenses figures came in at $17439.0 (Q4 2025), $17439.0 (Q3 2025), and $35425.0 (Q2 2025), per Business Quant data.